journal
https://read.qxmd.com/read/37704292/protein-disulfide-isomerase-family-mediated-redox-regulation-in-cancer
#1
REVIEW
Zhi-Wei Ye, Jie Zhang, Muhammad Aslam, Anna Blumental-Perry, Kenneth D Tew, Danyelle M Townsend
Protein disulfide isomerase (PDI) and its superfamilies are mainly endoplasmic reticulum (ER) resident proteins with essential roles in maintaining cellular homeostasis, via thiol oxidation/reduction cycles, chaperoning, and isomerization of client proteins. Since PDIs play an important role in ER homeostasis, their upregulation supports cell survival and they are found in a variety of cancer types. Despite the fact that the importance of PDI to tumorigenesis remains to be understood, it is emerging as a new therapeutic target in cancer...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37704291/mechanical-factors-driving-cancer-progression
#2
REVIEW
Jessanne Y Lichtenberg, Sydnie Tran, Priscilla Y Hwang
A fundamental step of tumor metastasis is tumor cell migration away from the primary tumor site. One mode of migration that is essential but still understudied is collective invasion, the process by which clusters of cells move in a coordinated fashion. In recent years, there has been growing interest to understand factors regulating collective invasion, with increasing number of studies investigating the biomechanical regulation of collective invasion. In this review we discuss the dynamic relationship between tumor microenvironment cues and cell response by first covering mechanical factors in the microenvironment and second, discussing the mechanosensing pathways utilized by cells in collective clusters to dynamically respond to mechanical matrix cues...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37704290/applications-of-tissue-specific-and-cancer-selective-gene-promoters-for-cancer-diagnosis-and-therapy
#3
REVIEW
Amit Kumar, Swadesh K Das, Luni Emdad, Paul B Fisher
Current treatment of solid tumors with standard of care chemotherapies, radiation therapy and/or immunotherapies are often limited by severe adverse toxic effects, resulting in a narrow therapeutic index. Cancer gene therapy represents a targeted approach that in principle could significantly reduce undesirable side effects in normal tissues while significantly inhibiting tumor growth and progression. To be effective, this strategy requires a clear understanding of the molecular biology of cancer development and evolution and developing biological vectors that can serve as vehicles to target cancer cells...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37704289/head-and-neck-cancer-treatment-in-the-era-of-molecular-medicine
#4
REVIEW
Subramanya Pandruvada, Remi Kessler, Ann Thai
Head and neck cancers are a heterogeneous group of highly aggressive tumors and collectively represent the sixth most common cancer worldwide. Most head and neck cancers are squamous cell carcinomas (HNSCCs). Current multimodal treatment concepts combine surgery, chemotherapy, irradiation, immunotherapy, and targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of HNSCC and revealed novel therapeutic targets and prognostic/predictive biomarkers. Notably, HNSCC is characterized by complex relations between stromal, epithelial, and immune cells within the tumor microenvironment (TME)...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37704288/setting-sail-maneuvering-shp2-activity-and-its-effects-in-cancer
#5
REVIEW
Colin L Welsh, Sarah Allen, Lalima K Madan
Since the discovery of tyrosine phosphorylation being a critical modulator of cancer signaling, proteins regulating phosphotyrosine levels in cells have fast become targets of therapeutic intervention. The nonreceptor protein tyrosine phosphatase (PTP) coded by the PTPN11 gene "SHP2" integrates phosphotyrosine signaling from growth factor receptors into the RAS/RAF/ERK pathway and is centrally positioned in processes regulating cell development and oncogenic transformation. Dysregulation of SHP2 expression or activity is linked to tumorigenesis and developmental defects...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37704287/lnc-ing-epigenetic-mechanisms-with-autophagy-and-cancer-drug-resistance
#6
JOURNAL ARTICLE
Sandhik Nandi, Atanu Mondal, Aritra Ghosh, Shravanti Mukherjee, Chandrima Das
Long noncoding RNAs (lncRNAs) comprise a diverse class of RNA molecules that regulate various physiological processes and have been reported to be involved in several human pathologies ranging from neurodegenerative disease to cancer. Therapeutic resistance is a major hurdle for cancer treatment. Over the past decade, several studies has emerged on the role of lncRNAs in cancer drug resistance and many trials have been conducted employing them. LncRNAs also regulate different cell death pathways thereby maintaining a fine balance of cell survival and death...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37704286/microsomal-glutathione-transferase-1-in-cancer-and-the-regulation-of-ferroptosis
#7
REVIEW
Jie Zhang, Zhi-Wei Ye, Ralf Morgenstern, Danyelle M Townsend, Kenneth D Tew
Microsomal glutathione transferase 1 (MGST1) is a member of the MAPEG family (membrane associated proteins in eicosanoid and glutathione metabolism), defined according to enzymatic activities, sequence motifs, and structural properties. MGST1 is a homotrimer which can bind three molecules of glutathione (GSH), with one modified to a thiolate anion displaying one-third-of-sites-reactivity. MGST1 has both glutathione transferase and peroxidase activities. Each is based on stabilizing the GSH thiolate in the same active site...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37704285/pfkp-more-than-phosphofructokinase
#8
REVIEW
Haizhen Wang, Tiffany Penaloza, Amanda J Manea, Xueliang Gao
Phosphofructokinase (PFK) is one of the key enzymes that functions in glycolysis. Studies show that PFKP regulates cell proliferation, apoptosis, autophagy, cell migration/metastasis, and stemness through glycolysis and glycolysis-independent functions. PFKP performs its function not only in the cytoplasm, but also at the cell membrane, on the mitochondria, at the lysosomal membrane, and in the nucleus. The functions of PFKP are extensively studied in cancer cells. PFKP is also highly expressed in certain immune cells; nevertheless, the study of the PFKP's role in immune cells is limited...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268403/preface
#9
EDITORIAL
Luni Emdad, Azeddine Atfi, Rajan Gogna, Jose G Trevino, Paul B Fisher
No abstract text is available yet for this article.
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268402/in-vivo-models-of-pancreatic-ductal-adenocarcinoma
#10
REVIEW
Vignesh Vudatha, Kelly M Herremans, Devon C Freudenberger, Christopher Liu, Jose G Trevino
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with high mortality rate. Within the next decade, PDAC is projected to become the second leading cause of cancer-associated death in the United States. Understanding the pathophysiology of PDAC tumorigenesis and metastases is crucial toward developing new therapeutics. One of the challenges in cancer research is generating in vivo models that closely recapitulate the genomic, histological, and clinical characteristics of human tumors. An ideal model for PDAC not only captures the tumor and stromal environment of human disease, but also allows for mutational control and is easy to reproduce in terms of time and cost...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268401/deciphering-epithelial-to-mesenchymal-transition-in-pancreatic-cancer
#11
REVIEW
Creighton Friend, Parash Parajuli, Mohammed S Razzaque, Azeddine Atfi
Epithelial to mesenchymal transition (EMT) is a complex cellular program that alters epithelial cells and induces their transformation into mesenchymal cells. While essential to normal developmental processes such as embryogenesis and wound healing, EMT has also been linked to the development and progression of various diseases, including fibrogenesis and tumorigenesis. Under homeostatic conditions, initiation of EMT is mediated by key signaling pathways and pro-EMT-transcription factors (EMT-TFs); however, in certain contexts, these pro-EMT regulators and programs also drive cell plasticity and cell stemness to promote oncogenesis as well as metastasis...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268400/tumor-microenvironment-interactions-with-cancer-stem-cells-in-pancreatic-ductal-adenocarcinoma
#12
REVIEW
António M Palma, Grace G Bushnell, Max S Wicha, Rajan Gogna
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer in the United States. Additionally, the low survival rate makes PDAC the third-leading cause of cancer-related mortality in the United States, and it is projected that by 2030, it will become the second-leading cause of cancer mortality. Several biological factors contribute to PDAC aggressiveness, and their understanding will narrow the gap from biology to clinical care of PDAC, leading to earlier diagnoses and the development of better treatment options...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268399/chemoresistance-in-pancreatic-ductal-adenocarcinoma-overcoming-resistance-to-therapy
#13
JOURNAL ARTICLE
Praveen Bhoopathi, Padmanabhan Mannangatti, Swadesh K Das, Paul B Fisher, Luni Emdad
Pancreatic ductal adenocarcinoma (PDAC), a prominent cause of cancer deaths worldwide, is a highly aggressive cancer most frequently detected at an advanced stage that limits treatment options to systemic chemotherapy, which has provided only marginal positive clinical outcomes. More than 90% of patients with PDAC die within a year of being diagnosed. PDAC is increasing at a rate of 0.5-1.0% per year, and it is expected to be the second leading cause of cancer-related mortality by 2030. The resistance of tumor cells to chemotherapeutic drugs, which can be innate or acquired, is the primary factor contributing to the ineffectiveness of cancer treatments...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268398/oncogenic-signaling-pathways-in-pancreatic-ductal-adenocarcinoma
#14
JOURNAL ARTICLE
Rahul Agrawal, Kedar Nath Natarajan
Pancreatic ductal adenocarcinoma (PDAC) is the most common (∼90% cases) pancreatic neoplasm and one of the most lethal cancer among all malignances. PDAC harbor aberrant oncogenic signaling that may result from the multiple genetic and epigenetic alterations such as the mutation in driver genes (KRAS, CDKN2A, p53), genomic amplification of regulatory genes (MYC, IGF2BP2, ROIK3), deregulation of chromatin-modifying proteins (HDAC, WDR5) among others. A key event is the formation of Pancreatic Intraepithelial Neoplasia (PanIN) that often results from the activating mutation in KRAS...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268397/tumor-heterogeneity-an-oncogenic-driver-of-pdac-progression-and-therapy-resistance-under-stress-conditions
#15
JOURNAL ARTICLE
António M Palma, Vignesh Vudatha, Maria Leonor Peixoto, Esha Madan
Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging disease usually diagnosed at advanced or metastasized stage. By this year end, there are an expected increase in 62,210 new cases and 49,830 deaths in the United States, with 90% corresponding to PDAC subtype alone. Despite advances in cancer therapy, one of the major challenges combating PDAC remains tumor heterogeneity between PDAC patients and within the primary and metastatic lesions of the same patient. This review describes the PDAC subtypes based on the genomic, transcriptional, epigenetic, and metabolic signatures observed among patients and within individual tumors...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268396/racial-disparities-in-pancreatic-cancer-clinical-trials-defining-the-problem-and-identifying-solutions
#16
JOURNAL ARTICLE
Allison N Martin, Rebecca A Snyder
Underrepresented minority patients with pancreatic cancer have differential access to cancer treatments, including clinical trials. The successful conduct and completion of clinical trials is critical to improve outcomes for patients with pancreatic cancer. Therefore, it is essential to consider how to maximize eligibility of patients for both therapeutic and non-therapeutic clinical trials. It is important for clinicians and for the health system to understand individual-, clinician-, and system-level barriers to recruitment, enrollment, and completion of clinical trials to alleviate bias...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268395/targeting-kras-in-pancreatic-cancer-emerging-therapeutic-strategies
#17
JOURNAL ARTICLE
Sajid Khan, Vivekananda Budamagunta, Daohong Zhou
KRAS, a predominant member of the RAS family, is the most frequently mutated oncogene in human pancreatic cancer (∼95% of cases). Mutations in KRAS lead to its constitutive activation and activation of its downstream signaling pathways such as RAF/MEK/ERK and PI3K/AKT/mTOR that promote cell proliferation and provide apoptosis evasion capabilities to cancer cells. KRAS had been considered 'undruggable' until the discovery of the first covalent inhibitor targeting the G12C mutation. While G12C mutations are frequently found in non-small cell lung cancer, these are relatively rare in pancreatic cancer...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268394/interplay-between-map-kinases-and-tumor-microenvironment-opportunity-for-immunotherapy-in-pancreatic-cancer
#18
JOURNAL ARTICLE
Sandeep Kumar, Sunil Kumar Singh, Piush Srivastava, Swathi Suresh, Basabi Rana, Ajay Rana
Pancreatic Ductal Adenocarcinoma (PDAC), commonly called pancreatic cancer, is aggressive cancer usually detected at a late stage, limiting treatment options with modest clinical responses. It is projected that by 2030, PDAC will be the second most common cause of cancer-related mortality in the United States. Drug resistance in PDAC is common and significantly affects patients' overall survival (OS). Oncogenic KRAS mutations are nearly uniform in PDAC, affecting over 90% of patients. However, effective drugs directed to target prevalent KRAS mutants in pancreatic cancer are not in clinical practice...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37268393/notch-signaling-pathway-in-pancreatic-tumorigenesis
#19
REVIEW
Wen-Cheng Chung, Keli Xu
The Notch signaling pathway is an evolutionary conserved signal transduction cascade that is critical to embryonic and postnatal development, but aberrant Notch signaling is also implicated in tumorigenesis of many organs including the pancreas. Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy in the pancreas, with a dismally low survival rate due to the late-stage diagnosis and peculiar therapeutic resistance. Upregulation of the Notch signaling pathway has been found in preneoplastic lesions as well as PDACs in genetically engineered mouse models and human patients, and inhibition of the Notch signaling suppresses tumor development and progression in mice as well as patient-derived xenograft tumor growth, suggesting a critical role for Notch in PDAC...
2023: Advances in Cancer Research
https://read.qxmd.com/read/37038315/collaborative-spirit-drives-the-field-of-tumor-glycobiology-a-preface-to-special-volume-on-cancer-glycobiology
#20
JOURNAL ARTICLE
Charles J Dimitroff, Karen L Abbott
No abstract text is available yet for this article.
2023: Advances in Cancer Research
journal
journal
23266
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.